Tissue-agnostic cancer therapies: promise, reality, and the path forward

Vivek Subbiah

Nat Commun. 2025 May 29;16(1):4972. doi: 10.1038/s41467-025-60369-1.
Abstract
Tissue-agnostic cancer therapies promise to revolutionize oncology by targeting molecular drivers. Sledge et al.�s study of nearly 300,000 tumors found 21.5% with tissue-agnostic indications. Despite nine FDA approvals, real-world implementation challenges persist. Progress depends on universal genomic testing, an oncogenomic-savvy workforce, innovative trials, updated regulations, and real-world evidence to maximize potential.